- Details
- Shilpa Gupta, MD presents data from ASCO 2020 on bladder cancer in this discussion with Ashish Kamat, MD, MBBS. Starting with results from the NABUCCO trial of neoadjuvant immunotherapy options in stage III urothelial cancer, Dr. Gupta highlights the results from the trial showing complete responses in 46% of patients. She surveys other trials presented at the 2020 ASCO meeting, including KEYNOTE-...
|
- Details
- Ashish Kamat, MD, MBBS, welcomes Andrea Apolo, MD, the chief of the Bladder Cancer Section at the National Cancer Institute, to review new arrivals in the therapeutic options for the management of metastatic bladder cancer. Dr. Apolo summarizes which checkpoint inhibitors were approved by the U.S. Federal Drug Administration (FDA) for second-line treatment of metastatic urothelial carcinoma as wel...
|
- Details
- Petros Grivas, MD, PhD, joins Alicia Morgans, MD, MPH, to review updates from the virtual ASCO 2020 meeting in the muscle-invasive bladder cancer setting. Dr. Grivas first provides an overview of the IMvigor010 trial which showed that disease-free survival was not prolonged with the addition of atezolizumab after neoadjuvant therapy in patients with muscle-invasive disease. The JAVELIN 100 trial,...
|
- Details
- Makarand Khochikar, President of the Urological society of India –West zone and Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital in Miraj, joins Ashish Kamat, MD to discuss the case of a 70-year-old patient who presented with left-side loin pain and intermittent hematuria. An ultrasound and CT scan revealed a solid-lesion in the left kidney, lesions in the left...
|
- Details
- Alicia Morgans, MD, MPH, and Petros Grivas, MD, PhD, discuss the recent updates in the metastatic urothelial carcinoma (mUC) disease space. Together they discuss multiple presentations given during the virtual ASCO 2020 including the IMvigor010 trial. They discuss other adjuvant immunotherapy trials for mUC, as well as new results from IMvigor130 assessing biomarkers. Dr. Morgans and Dr. Grivas al...
|
- Details
- Cora Sternberg, MD, FACP, an investigator on the phase 3 JAVELIN Bladder 100 trial shares the study design, rationale, and key outcomes from the trial. The JAVELIN Bladder 100 trial is a phase 3 randomized study for maintenance avelumab therapy in patients who derived disease response or stabilization from first-line platinum-based chemotherapy for advanced urothelial cancer. In this conversation...
|
- Details
- Ali Khaki and Petros Grivas come together to discuss a study Ali Khaki presented at the 2020 ASCO meeting, on the cost-effectiveness of atezolizumab added to first-line platinum chemotherapy for Advanced Urothelial Cancer. He with Dr. Grivas provides further insight into how this treatment plan was assessed, while also giving context regarding how cost-effectiveness is measured in cancer patients....
|
- Details
- Bishoy Faltas joins Alicia Morgans to discuss the cutting edge aspects of his research on urothelial cancer. Dr. Faltas shares information on the CLONEVO Trial and his team’s initial efforts on integrating machine learning and artificial intelligence in the care of bladder cancer patients. Biographies: Bishoy M. Faltas, MD, Director of Bladder Cancer Research, Englander Institute for Precision Med...
|
- Details
- The current standard of care for patients with localized muscle-invasive bladder cancer involves neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. Unfortunately, even with chemotherapy and surgery, cancer recurrence is common, with a 5-year survival rate of 50—60%. Thus, additional strategies are necessary to help patients achieve long term survival. Thomas Powles and Matthe...
|
- Details
- The phase III JAVELIN Bladder 100 trial was the first urothelial carcinoma plenary session at an ASCO annual meeting in the meeting's history and Thomas Powles lead principal investigator on the trial along with Matthew Galsky join Alicia Morgans sharing results of this trial. This was a maintenance trial where first-line treatment with avelumab extended the survival over best supportive care (BSC...
|
